Technical Analysis for CBIO - Catalyst Inc.

Grade Last Price % Change Price Change
grade F 8.93 6.95% 0.58
CBIO closed up 6.95 percent on Friday, February 15, 2019, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CBIO trend table...

Date Alert Name Type % Chg
Feb 15 Crossed Above 50 DMA Bullish 0.00%
Feb 15 MACD Bullish Centerline Cross Bullish 0.00%
Feb 15 180 Bullish Setup Bullish Swing Setup 0.00%
Feb 14 Bearish Engulfing Bearish 6.95%
Feb 14 Fell Below 50 DMA Bearish 6.95%
Feb 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.95%
Feb 14 Inside Day Range Contraction 6.95%
Feb 13 20 DMA Support Bullish 1.71%
Feb 13 Crossed Above 50 DMA Bullish 1.71%
Feb 13 Upper Bollinger Band Touch Strength 1.71%

Older signals for CBIO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Catalyst Biosciences, Inc., a biopharmaceutical company, focuses on discovering and developing novel biopharmaceutical products based on engineered human proteases. The company designs its proteases to promote hemostasis and to prevent inflammation. Its pipeline of protease therapeutics include CB 813d/PF-05280602, an engineered Factor VIIa drug candidate that completed a Phase 1 clinical trial evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity. The company's pre-clinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of hemophilia B inhibitor patients; and an engineered Factor Xa for hemophilia and the control of bleeding in non-hemophilia patients. It also develops factor C3 for the prevention of renal delayed graft function and the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.
Biopharmaceutical Inflammation Molecular Biology Cell Biology Anatomy Pharmacokinetics Macular Degeneration Hemophilia Treatment Of Hemophilia Coagulation System Biopharmaceutical Products Coagulation Pharmacodynamics Factor X
Is CBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.15
52 Week Low 6.2
Average Volume 265,680
200-Day Moving Average 12.4154
50-Day Moving Average 8.5708
20-Day Moving Average 8.2985
10-Day Moving Average 8.529
Average True Range 0.6777
ADX 12.24
+DI 19.0642
-DI 17.93
Chandelier Exit (Long, 3 ATRs ) 7.256899999999999
Chandelier Exit (Short, 3 ATRs ) 9.4831
Upper Bollinger Band 9.0892
Lower Bollinger Band 7.5078
Percent B (%b) 0.9
BandWidth 19.056456
MACD Line 0.0156
MACD Signal Line -0.0566
MACD Histogram 0.0721
Fundamentals Value
Market Cap 38.48 Million
Num Shares 4.31 Million
EPS -14.07
Price-to-Earnings (P/E) Ratio -0.63
Price-to-Sales 35.66
Price-to-Book 0.66
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.01
Resistance 3 (R3) 9.93 9.48 9.83
Resistance 2 (R2) 9.48 9.21 9.53 9.77
Resistance 1 (R1) 9.21 9.04 9.35 9.29 9.71
Pivot Point 8.76 8.76 8.83 8.81 8.76
Support 1 (S1) 8.49 8.49 8.63 8.57 8.15
Support 2 (S2) 8.04 8.32 8.09 8.09
Support 3 (S3) 7.77 8.04 8.03
Support 4 (S4) 7.85